• 1\. Age ≥18 years old, gender unlimited;

• 2\. Abnormal B cell immunotyping was CD19 positive;

• 3\. Patients diagnosed with B-cell acute lymphoblastic leukemia by histological or immunotyping;

• 4\. Meets the diagnosis of relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and includes any of the following conditions:

‣ No CR was obtained after standard chemotherapy;

⁃ CR was induced for the first time, but the duration of CR was less than 12 months;

⁃ R/R B-ALL that does not work after the first or more remedial treatments;

⁃ Two or more relapses;

• 5\. The researchers believed that the patient had been adequately treated, such as auto-HSCT, auto-CART could not be prepared or preparation failed. Autologous CAR-T preparation failure was defined as including too few autologous lymphocytes (\<1×109) or insufficient expansion during preparation or failure to meet the release criteria;

• 6\. Total bilirubin ≤51 ( μmol/L), alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal, creatinine ≤176.8 (μmol/L);

• 7\. Absolute neutrophil count: ≥ 0.5×109/L; Platelet: ≥ 30×109/L; Hemoglobin ≧60g/L;

• 8\. Echocardiography showed left ventricular ejection fraction (LVEF) ≥40%;

• 9\. The estimated survival is more than 3 months;

• 10\. ECOG score 0-2;

• 11\. Women and men who are fertile must consent to the use of appropriate contraception before entering the study, during study participation, and for 6 months after transfusion (the safety of this therapy for the unborn child is not known, with unknown risks);

• 12\. Subjects who are willing to participate in the study are able to understand and have the ability to sign informed consent.